Tris

ANGUS ACHIEVES 2022 ECOVADIS GOLD RATING STATUS FOR SUSTAINABILITY PERFORMANCE

Retrieved on: 
Thursday, June 16, 2022
Sustainability, Sustainable procurement, List of life sciences, Quality, Buffer, ISO, AMP, Gold, Safety, Product stewardship, Human rights, Environment, Achievement, Company, ANGUS, CSR, Biotechnology, Leadership, Industry, TRIS, Health, John F. Ring, Social responsibility, Tris, Renewable energy, Fine chemical

BUFFALO GROVE, Ill., June 16, 2022 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced it was awarded the 2022 Gold Recognition Level in sustainability performance by EcoVadis.

Key Points: 
  • BUFFALO GROVE, Ill., June 16, 2022 /PRNewswire/ --ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced it was awarded the 2022 Gold Recognition Level in sustainability performance by EcoVadis.
  • The Gold rating places ANGUS in the 92nd percentile of the tens of thousands of global companies assessed by EcoVadis each year.
  • "We are honored to receive the EcoVadis Gold rating for our sustainability performance," said Dr. Pam Spencer, Vice President, Regulatory, Product Stewardship, Quality and Sustainability.
  • ANGUS invites its commercial partners to request direct access to ANGUS' 2022 evaluation results from EcoVadis as part of their supplier evaluation process.

Spectrum Chemical Enters into New Distribution Arrangement with ANGUS Chemical Company to Provide Select TRIS Buffers and Derivatives for Life Sciences and Biopharmaceuticals Markets in United States and Canada

Retrieved on: 
Thursday, June 9, 2022
Medical Supplies, Packaging, Chemicals, Plastics, Manufacturing, Biotechnology, Health, Pharmaceutical, Other Science, Science, Buffer, Company, Research, Biotechnology, TRIS, Business development, Luchsinger, Tris, FCC, Multimedia, ISO, CGMP, ANGUS, Fine chemical

Today, ANGUS is the worlds largest and only fully integrated manufacturer of TRIS buffers.

Key Points: 
  • Today, ANGUS is the worlds largest and only fully integrated manufacturer of TRIS buffers.
  • We are committed to delivering the fullest range of high-quality chemicals necessary for every bioprocessing stage, from development through commercialization.
  • Luchsinger pointed out that the new ANGUS-branded products also complement Spectrum Chemicals current bioprocessing portfolio such as its bioCERTIFIED product line .
  • Spectrum Chemical supplies hundreds of unique cell culture additives in a wide range of packaging sizes throughout the world.

Univar Solutions and ANGUS Expand Distribution Agreement in Europe to Include the Homecare & Industrial Cleaning Market

Retrieved on: 
Wednesday, May 25, 2022
Industry, Company, Living Together, Growing Together, Buffer, U.S. Securities and Exchange Commission, Personal care, OXO-biodegradation, Solution, Health, HIC, TRIS, Natural rubber, Transport, COVID-19, AMP, Adhesive, Beauty, Workforce, Sealant, Securities Act of 1933, BPC, Securities Exchange Act of 1934, Accident, Biotechnology, ULTRA, Industrial, CASE, Forward-looking statement, Terminology, Univar Solutions, Glass, Energy Independence and Security Act of 2007, Security (finance), Texas Homecare, Tris, Center, ISO, ANGUS, NYSE, Detergent, Fine chemical, Renewable energy, Risk management

ROTTERDAM, Netherlands, May 25, 2022 /PRNewswire/ -- Europe, Univar B.V., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added services, announced today the expansion of its distribution agreement with ANGUS Chemical Company ("ANGUS"), a leading global manufacturer of specialty chemicals for life sciences, home and personal care and industrial markets, to include the pan-European Homecare & Industrial Cleaning (HIC) market. This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.

Key Points: 
  • This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.
  • Under the expanded agreement, Univar Solutions will also offer ULTRA PC-grades of ANGUS amino alcohols for homecare and industrial cleaning customers who seek low secondary amine content.
  • "At Univar Solutions, we support homecare and industrial cleaning manufacturers around the globe through a hub-and-spoke model of Solution Centers offering prototyping, trend kits, performance and raw material evaluations and formulation as well as technical assistance," said Aaron Lee, global vice president for Homecare & Industrial Cleaning at Univar Solutions.
  • "We are excited to expand our existing agreement with Univar Solutions and their broad network and deep expertise in homecare and industrial cleaning applications to better serve formulators and manufacturers across Europe that are using ANGUS chemistries."

Univar Solutions and ANGUS Expand Distribution Agreement in Europe to Include the Homecare & Industrial Cleaning Market

Retrieved on: 
Wednesday, May 25, 2022
Industry, Company, Living Together, Growing Together, Buffer, U.S. Securities and Exchange Commission, Personal care, OXO-biodegradation, Multimedia, View, Solution, Health, HIC, TRIS, Natural rubber, Transport, COVID-19, AMP, Adhesive, Beauty, Workforce, Sealant, Securities Act of 1933, BPC, Securities Exchange Act of 1934, Accident, Biotechnology, ULTRA, Industrial, CASE, Forward-looking statement, Terminology, Univar Solutions, Glass, Energy Independence and Security Act of 2007, Security (finance), Texas Homecare, Tris, Center, ISO, ANGUS, NYSE, Detergent, Fine chemical, Renewable energy, Risk management

ROTTERDAM, Netherlands, May 25, 2022 /PRNewswire/ -- Europe, Univar B.V., a subsidiary of Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global commodity and specialty chemical and ingredient distributor and provider of value-added services, announced today the expansion of its distribution agreement with ANGUS Chemical Company ("ANGUS"), a leading global manufacturer of specialty chemicals for life sciences, home and personal care and industrial markets, to include the pan-European Homecare & Industrial Cleaning (HIC) market. This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.

Key Points: 
  • This agreement will further enable Univar Solutions to provide its customers with expanded access to specialty cleaning ingredients alongside comprehensive technical innovation and sourcing support.
  • Under the expanded agreement, Univar Solutions will also offer ULTRA PC-grades of ANGUS amino alcohols for homecare and industrial cleaning customers who seek low secondary amine content.
  • "At Univar Solutions, we support homecare and industrial cleaning manufacturers around the globe through a hub-and-spoke model of Solution Centers offering prototyping, trend kits, performance and raw material evaluations and formulation as well as technical assistance," said Aaron Lee, global vice president for Homecare & Industrial Cleaning at Univar Solutions.
  • "We are excited to expand our existing agreement with Univar Solutions and their broad network and deep expertise in homecare and industrial cleaning applications to better serve formulators and manufacturers across Europe that are using ANGUS chemistries."

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. announce the launch of Ketorolac Tromethamine Tablets USP, 10 mg in the U.S. market

Retrieved on: 
Tuesday, May 24, 2022
Science, Other Science, Research, Pharmaceutical, Alternative Medicine, Health, FDA, Other Health, USE, Hemostasis, RDY, Laboratory, Risk, History, NOT, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Ketorolac, Bleeding, RISK, Asthma, Automated Import Information System, Tris, Aspirin, Patient, Hives, Gastrointestinal bleeding, Kidney, Stomach, Myocardial infarction, Stroke, Human, Analgesic, Ulcerative colitis, CABG, NSE, IQVIA, Tablet, NSAID, Dan Senor, Extrapyramidal system, Pregnancy, Pain, Nonsteroidal anti-inflammatory drug, BSE, USFDA, Peptic ulcer disease, WITH, Possible Side Effects, NYSE, Perforation, CEO, Generic drug, Dietary supplement, Pharmaceutical industry, Birth control, Medical imaging, Phosphorus

Dr. Reddys Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.

Key Points: 
  • Dr. Reddys Ketorolac Tromethamine Tablets USP, 10 mg, are available in bottle count sizes of 100.
  • The total combined duration of use of ketorolac tromethamine tablets and ketorolac tromethamine should not exceed 5 days.
  • Ketorolac tromethamine tablets are not indicated for use in pediatric patients and they are NOT indicated for minor or chronic painful conditions.
  • Ketorolac tromethamine, including ketorolac tromethamine tablets can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal.

Athena Bioscience Announces Launch of Nexiclon™ XR, the Only Once-Daily Clonidine Extended-Release Tablets for Treatment of Hypertension

Retrieved on: 
Thursday, March 3, 2022
Ketan, Myocardial infarction, Risk, Conditional sentence, Patient, Approved Drug Products with Therapeutic Equivalence Evaluations, Cosmo, Anau, Quality of life, Heart failure, GA, Cardiovascular disease, LLC, BP, IM, Cohort study, Adherence (medicine), Athena, Compliance, Orange Book, Medicine, Tris, CEO, Medical Care (journal), Stroke, ADHD, Meta-analysis, Technology, Clonidine, Food and Drug Administration, Hypertension, Santino Di Matteo, Pharmaceutical industry, Medical device

"The launch of Nexiclon XR demonstrates Tris' continued success bringing differentiated technology-based medications to market," said Tris CEO Ketan Mehta.

Key Points: 
  • "The launch of Nexiclon XR demonstrates Tris' continued success bringing differentiated technology-based medications to market," said Tris CEO Ketan Mehta.
  • "Given their proven track record, we are delighted that Athena is our partner, launching this important cardiovascular product."
  • Nexiclon is based on Tris's LiquiXRdrug delivery technology, which has led to the development of multiple first-in-category products.
  • Athena Bioscience, LLCis a specialty pharmaceutical company that seeks to enhance medical options for both healthcare professionals and patients through innovative solutions to unmet challenges.

Amneal Expands Injectables Portfolio with 4 New Products

Retrieved on: 
Thursday, February 17, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NYSE, Patient, Food, Risk, Carboprost, Company, Federation, CGT, Weather, Injection, Forward-looking statement, Medication, U.S. Securities and Exchange Commission, Security (finance), Baclofen, Annual report, Degenerative disease, SVP, Regulation of tobacco by the U.S. Food and Drug Administration, Tris, Abbreviated New Drug Application, USP, FDA, Saol, Generic, ANDA, Central nervous system, LVP, Private Securities Litigation Reform Act, Growth, Dexamethasone, Research, Investment, Amneal Pharmaceuticals, COVID-19, Azacitidine, Atropine, Peptide, Pharmaceutical industry, Fine chemical, Generic drug, Risk management

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced the approval of four generic injectables products.
  • An important element of Amneals long-term growth strategy is expanding our injectables business, and todays announcement of four new approvals is another key step.
  • The Company has a diverse portfolio of approximately 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars.
  • In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs.

ANGUS Completes Expansion Of Louisiana Site To Include TRIS AMINO™ Hydrochloride Production

Retrieved on: 
Tuesday, February 15, 2022
List of life sciences, CEO, Hydrogen chloride, Company, ANGUS, ISO, ISO 9001:2015, Tris, Biotechnology, Buffer, CGMP, PH, Multi, Growth, Quality control, Eye, AMP, Fine chemical, TRIS

BUFFALO GROVE, Ill., Feb. 15, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the expansion of its Sterlington, Louisiana manufacturing facility to include commercial production of TRIS AMINO Hydrochloride (HCl) products .

Key Points: 
  • BUFFALO GROVE, Ill., Feb. 15, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the expansion of its Sterlington, Louisiana manufacturing facility to include commercial production of TRIS AMINO Hydrochloride (HCl) products .
  • "As the world's largest and only fully integrated manufacturer of TRIS AMINO tromethamine buffers, ANGUS is uniquely positioned to provide 100% traceability and the most secure, sustainable supply of TRIS AMINO HCl products on the market today."
  • Today, with the expansion into commercial production of TRIS AMINO HCl products, ANGUS is well-positioned to ensure supply chain security and continuity for our critical chemistries."
  • Multi-batch samples of ANGUS-manufactured TRIS AMINO HCl and TRIS AMINO HCl Biologics Plus products are now available for customer qualification.

For the Third Year in a Row, APSARD Announces the Tris Research Award in ADHD

Retrieved on: 
Tuesday, February 15, 2022
Ketan, Patient, Attention deficit hyperactivity disorder, Epidemiology, CEO, Annual general meeting, Organization, Decision-making, Technology, Partnership, ADHD, Research, Diagnosis, Tris, Pharmaceutical industry, Medical device

During the 2022 APSARD Annual Meeting, held virtually on 14-16 January 2022, APSARD announced the 2022 recipients of the research award to advance and recognize outstanding research in the field of ADHD.

Key Points: 
  • During the 2022 APSARD Annual Meeting, held virtually on 14-16 January 2022, APSARD announced the 2022 recipients of the research award to advance and recognize outstanding research in the field of ADHD.
  • The Tris Research Award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders.
  • The 2022 Tris Research Award recipients were chosen from all scientific posters presented at the 2022 APSARD Annual Meeting, held virtually on 14-16 January 2022.
  • The Organization works to improve the quality of care for ADHD patients through shared research, best practices, evidence-based education and training.

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age

Retrieved on: 
Friday, October 29, 2021
Safety, Science, Death, Infection, Buffer, Vaccine, Multisystem inflammatory syndrome, VAERS, Advisory Committee on Immunization Practices, Red, Vaccination, Caregiver, EUA, Pfizer, FDA, Headache, Center for Biologics Evaluation and Research, Immunization, Food, RNA, Severe acute respiratory syndrome coronavirus 2, Nausea, Pericarditis, Risk, Center, Fever, ICU, Regulation of tobacco by the U.S. Food and Drug Administration, Time, Appetite, Fatigue, Clinical trial, COVID-19, Centers for Disease Control and Prevention, Inflammation, Tris, Research, CDC, Commissioner of Food and Drugs, Hospital, Heart, Parent, Swelling, Myocarditis, Chills, Pharmaceutical industry

Key points for parents and caregivers:

Key Points: 
  • Key points for parents and caregivers:
    Effectiveness: Immune responses of children 5 through 11 years of age were comparable to those of individuals 16 through 25 years of age.
  • In that study, the vaccine was 90.7% effective in preventing COVID-19 in children 5 through 11.
  • In the U.S., COVID-19 cases in children 5 through 11 years of age make up 39% of cases in individuals younger than 18 years of age.
  • According to the CDC, approximately 8,300 COVID-19 cases in children 5 through 11 years of age resulted in hospitalization.